AAV Purification: Solving Downstream Challenges

The rapid expansion of gene therapy programs targeting a wide range of diseases has been driven in large part by advances in our understanding of adeno-associated virus (AAV) vectors, particularly regarding their safety and delivery efficiency. As these therapies move from research to clinical application, the purification of AAV vectors has emerged as a critical and complex step in the development process. Effective downstream purification is essential for producing high-quality vectors at scale, and it presents a number of technical and operational challenges that must be addressed to ensure consistent yield, purity, and regulatory compliance.

In this roundtable discussion, Dr. Ganesh Krishnamoorthy, Director of Downstream Process Development at Forge Biologics; Stephen Soltys, Vice President of Process Development at Kriya Therapeutics; and Chantelle Gaskin, Field Application Scientist at Thermo Fisher Scientific, share their insights, strategies, and lessons learned from the field. Their collective expertise will offer valuable perspectives for researchers and developers working to advance the next generation of gene therapies.

Topics include current industry trends, the evolving potential for platform-based solutions, and the continuous demand for innovation to overcome persistent bottlenecks in downstream processing.